Charles Schwab’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$11.7M	Sell	3,808,798 -185,853	-5%	-$718K	﹤0.01%	2029
2025 Q4	$16.3M	Buy	3,994,651 +549,631	+16%	+$2.72M	﹤0.01%	1876
2025 Q3	$16.8M	Buy	3,445,020 +855,818	+33%	+$4.49M	﹤0.01%	1847
2025 Q2	$13.1M	Buy	2,589,202 +310,801	+14%	+$1.53M	﹤0.01%	1886
2025 Q1	$12.1M	Buy	2,278,401 +4,398	+0.2%	+$32.1K	﹤0.01%	1863
2024 Q4	$15.4M	Buy	2,274,003 +333,323	+17%	+$2.24M	﹤0.01%	1829
2024 Q3	$12.8M	Buy	1,940,680 +288,926	+17%	+$2.07M	﹤0.01%	1915
2024 Q2	$12.4M	Buy	1,651,754 +438,742	+36%	+$3.83M	﹤0.01%	1934
2024 Q1	$12.1M	Buy	1,213,012 +22,130	+2%	+$246K	﹤0.01%	1900
2023 Q4	$11.7M	Buy	1,190,882 +32,916	+3%	+$235K	﹤0.01%	1901
2023 Q3	$8.86M	Buy	1,157,966 +157,189	+16%	+$1.57M	﹤0.01%	1979
2023 Q2	$7.48M	Buy	1,000,777 +16,838	+2%	+$118K	﹤0.01%	2050
2023 Q1	$6.56M	Sell	983,939 -742	-0.1%	-$5.89K	﹤0.01%	2075
2022 Q4	$7.59M	Buy	984,681 +80,177	+9%	+$786K	﹤0.01%	2003
2022 Q3	$9.62M	Buy	904,504 +476,162	+111%	+$4.82M	﹤0.01%	1858
2022 Q2	$3.49M	Buy	428,342 +55,178	+15%	+$369K	﹤0.01%	2351
2022 Q1	$2.67M	Sell	373,164 -4,075	-1%	-$43.3K	﹤0.01%	2549
2021 Q4	$6.46M	Buy	377,239 +194,467	+106%	+$3.66M	﹤0.01%	2224
2021 Q3	$4.21M	Buy	182,772 +17,891	+11%	+$507K	﹤0.01%	2456
2021 Q2	$6.02M	Buy	+164,881	New	+$4.88M	﹤0.01%	2257